BDX logo Becton, Dickinson and Company +
Becton, Dickinson and Company
+

Becton, Dickinson and Company (BDX) Business News

Track Becton, Dickinson and Company in real time with a live news feed covering Becton, Dickinson and Company stock news, official press releases, company announcements, and an archive of historical Becton, Dickinson and Company news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection

BD Extends Leadership in Advanced Tissue Regeneration Through Continued Clinical Innovation

PRNewsWire

6:50 AM | Thursday | Aug 27, 2026

news photo
Loading...

STANCE trial surpasses a key enrollment milestone, advancing the clinical evaluation of GalaFLEX LITEâ„¢ Scaffold and generating evidence to support its use in breast revision surgery for capsular contracture FRANKLIN LAKES, N.J., Aug. 27, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a significant milestone in its advanced tissue regeneration strategy and expansion efforts with the STANCE clinical trial evaluating GalaFLEX LITEâ„¢ Scaffold in breast revision surgery for capsular contracture.

Read full article redirect
6:50 AM | Thursday | Aug 27, 2026

BD Extends Leadership in Advanced Tissue Regeneration Through Continued Clinical Innovation

PRNewsWire

STANCE trial surpasses a key enrollment milestone, advancing the clinical evaluation of GalaFLEX LITEâ„¢ Scaffold and generating evidence to support its use in breast revision surgery for capsular contracture FRANKLIN LAKES, N.J., Aug. 27, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a significant milestone in its advanced tissue regeneration strategy and expansion efforts with the STANCE clinical trial evaluating GalaFLEX LITEâ„¢ Scaffold in breast revision surgery for capsular contracture.

Read full article arrow
News Thumbnail
6:50 AM | Thursday | Aug 27, 2026

BD Extends Leadership in Advanced Tissue Regeneration Through Continued Clinical Innovation

PRNewsWire

STANCE trial surpasses a key enrollment milestone, advancing the clinical evaluation of GalaFLEX LITEâ„¢ Scaffold and generating evidence to support its use in breast revision surgery for capsular contracture FRANKLIN LAKES, N.J., Aug. 27, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a significant milestone in its advanced tissue regeneration strategy and expansion efforts with the STANCE clinical trial evaluating GalaFLEX LITEâ„¢ Scaffold in breast revision surgery for capsular contracture.

Read full article arrow
News Thumbnail
4:30 PM | Monday | Aug 17, 2026

BD Appoints Gary Sorsher as Chief Quality Officer; Jeff Silvestri to Retire

PRNewsWire

FRANKLIN LAKES, N.J., Aug. 17, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Gary Sorsher has been named executive vice president and chief quality officer, effective September 8.

Read full article arrow
News Thumbnail
6:50 AM | Wednesday | Aug 12, 2026

BD Accelerates Advanced Tissue Regeneration Strategy with Landmark PREVENT Trial

PRNewsWire

Enrollment completed in the first large-scale randomized study evaluating Phasixâ„¢ Mesh for incisional hernia prevention, a significant unmet need following abdominal surgery FRANKLIN LAKES, N.J., Aug. 12, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a significant milestone in its advanced tissue regeneration strategy and expansion efforts with successful completion of enrollment in the PREVENT clinical trial evaluating Phasixâ„¢ Mesh for the prevention of incisional hernias.

Read full article arrow
News Thumbnail
6:30 AM | Thursday | Aug 6, 2026

BD Reports Third Quarter Fiscal 2026 Financial Results

PRNewsWire

Revenue of $5.0 billion increased 5.4% as reported, 4.4% FXN GAAP and adjusted diluted EPS from continuing operations of $1.64 and $3.
23, respectively Year-to-date cash from continuing operations increased 33.3% to $2.1 billion and free cash flow increased 44.6% to $1.7 billion Company updates full-year guidance to reflect ongoing momentum, expects revenue growth toward the high end of its range and raises midpoint of adjusted diluted EPS guidance FRANKLIN LAKES, N.
J., Aug. 6, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its fiscal 2026 third quarter, which ended June 30, 2026.

Read full article arrow
News Thumbnail
6:54 AM | Wednesday | Jul 29, 2026

EMS and BD expand access to GLP-1 therapies in Brazil with semaglutide launch

PRNewsWire

Collaboration pairs leadership in pharmaceuticals and advanced drug delivery technology to support a consistent, reliable treatment experience for metabolic disease patients. FRANKLIN LAKES, N.J.

Read full article arrow
News Thumbnail
6:55 AM | Wednesday | Jul 22, 2026

Mike Garrison to Retire from BD

PRNewsWire

FRANKLIN LAKES, N.J., July 22, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Dr. Michael (Mike) Garrison has informed the company of his intent to retire after more than 20 years with BD, effective Oct. 2.

Read full article arrow
News Thumbnail
4:15 PM | Thursday | Jul 9, 2026

BD to Announce Financial Results for its Third Quarter of Fiscal 2026

PRNewsWire

FRANKLIN LAKES, N.J., July 9, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that BD management will host an audio webcast at 8 a.m.

Read full article arrow
News Thumbnail
6:50 AM | Tuesday | Jun 23, 2026

BD Awarded Vizient Innovative Technology Contract for CentroVena Oneâ„¢ Insertion System

PRNewsWire

Recognition from Vizient validates CentroVena One™ as a breakthrough innovation designed to simplify central line insertion and enhance patient and clinician safety FRANKLIN LAKES, N.J., June 23, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that its BD® CentroVena One™ Insertion System has been awarded an Innovative Technology contract from Vizient®, the nation's largest provider-driven healthcare performance improvement company.

Read full article arrow
News Thumbnail
6:50 AM | Thursday | May 21, 2026

BD Delivers Kidney Stone Care for Urology Teams with the Elyraâ„¢ Thulium Fiber Laser System

PRNewsWire

New laser system is designed to help urology teams enhance efficiency, versatility, and procedural workflow across stone management and soft tissue procedures. FRANKLIN LAKES, N.J.

Read full article arrow
News Thumbnail
6:50 AM | Monday | May 18, 2026

Peter Menziuso Named EVP and President, BD Interventional

PRNewsWire

FRANKLIN LAKES, N.J., May 18, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Peter Menziuso has been named executive vice president and president, BD Interventional, effective June 1.

Read full article arrow
News Thumbnail